Authors

Shubham Pant, MD, MBBS, is a professor in the Department of Gastrointestinal Medical Oncology in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center

Latest:

Personalized Treatment Considerations Guide First-Line Chemo Use in Pancreatic Cancer: With Shubham Pant, MD, MBBS

Dr Pant discusses factors that drive frontline chemotherapy selection for metastatic pancreatic cancer and the role of NALIRIFOX in this treatment setting.

Shubham Pant, MD, MD Anderson Cancer Center

Latest:

TRK Inhibitors in Lung and GI Cancers

Shubham Pant, MD, The University of Texas MD Anderson Cancer Center

Shuo

Shuo Ma, MD, PhD, Feinberg School of Medicine at Northwestern Medicine

Shuo Ma, MD, PhD, Northwestern University Feinberg School of Medicine

Shuo Ma, MD, PhD, Northwestern University Feinberg School of Medicine, Susan M. O’Brien, MD, UC Irvine Health

Shuo Ma, MD, PhD, Robert H. Lurie Comprehensive Cancer Center

Shweta Gupta, MD

Latest:

Tricks of the Trade: 4 Decades of Wisdom

Medical oncology can be a very demanding and taxing field.

Siamak Daneshmand, MD

Sia Daneshmand MD, is a professor of urology, clinical scholar designation; director of Clinical Research in the urologic oncology fellowship at Keck School of Medicine, University of Southern California.

Latest:

Dr Daneshmand on Using TAR-200 to Address Unmet Needs in BCG-Unresponsive NMIBC

Sia Daneshmand MD, discusses how the intravesical therapy TAR-200 could address unmet needs for patients with high-risk, BCG-unresponsive NMIBC with CIS.

Siavash Jabbari, MD

Latest:

Dr. Jabbari on the Potential for Implantable Cardiac Devices to Malfunction Following RT

Siavash Jabbari, MD, discusses the potential for implantable cardiac devices to malfunction following radiation therapy.

Sibel Blau, MD

Latest:

Dr. Blau on a Research-Based Approach to Meet OCM Requirements

Sibel Blau, MD, medical oncology provider, medical director, Hematology/Oncology, Northwest Medical Specialties, discusses a value-based care model for oncology at the Association of Community Cancer Centers (ACCC) National Oncology Conference.

Sibylle Loibl, MD, PhD

Latest:

Dr. Loibl Discusses GeparSepto Trial in Breast Cancer

Sibylle Loibl, MD, PhD, co-chair of the German Breast Group (GBG) and associate professor at the University of Frankfurt, discusses the GeparSepto trial in subgroups of patients with breast cancer.

Siddhartha Devarakonda, MD

Latest:

Dr. Devarakonda on Second-line Treatment Options in Small Cell Lung Cancer

Siddhartha Devarakonda, MD, MBBS, discusses second-line treatment considerations for patients with small cell lung cancer.

Sigrid Eckardt

Latest:

A Closer Look at BRAF Melanoma Testing Reveals Intricacies of V600 Mutation

BRAF mutation testing has become an essential tool in the diagnostic workup and management of patients with advanced melanoma. Activating mutations of BRAF are present in 40% to 60% of all melanoma cases, with more than 90% of mutations found at codon 600 in exon 15.

Silas Inman

Silas is the senior vice president, content, at MJH Life Sciences. He began his career at MJH in 2011 as a Web Editor on OncLive. From this role, he moved into managing the social media across the organization and then into broader roles across the content department, first taking on management of HCPLive.

Latest:

TERN-701 Elicits Deep Responses in Heavily Pretreated CP-CML

TERN-701 yielded a high response rate with deep molecular responses in heavily pretreated chronic phase chronic myeloid leukemia.

Silvia Chiara Formenti, MD

Latest:

Dr. Formenti on Recent Progress With HER2-Targeted Therapy

Silvia Chiara Formenti, MD, chair, Department of Radiation Oncology, Weill Cornell, associate director, Meyer Cancer Center, radiation oncologist-in-chief, NewYork-Presbyterian Hospital, discusses the recent progress with HER2-targeted therapy in the treatment of breast cancer.

Silvia Formenti, MD

Latest:

Dr. Formenti on Combining Radiotherapy With Immunotherapy in NSCLC

Silvia Formenti, MD, chair of Radiation Oncology at Weill Cornell Medical College and radiation oncologist-in-chief at Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses combining radiotherapy with immunotherapy in non-small cell lung cancer (NSCLC).

Silvia Novello, MD, PhD

Latest:

Dr. Novello on the Gray Areas in Lung Cancer Care

Silvia Novello, MD, PhD, assistant professor, Thoracic Oncology Unit, University of Turin, San Luigi Hospital, Orbassano, Italy, discusses some of the "gray areas" that require more research for the treatment of patients with lung cancer.

Simon Abi aad, MD

Latest:

Our Patients' Care Comes First, Even During Natural Disasters

Simon Abi Aad, MD, discusses caring for patients during Hurricane Irma.